New catheter lock solution could cut ICU infections
NCT ID NCT07366372
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a taurolidine-based lock solution can prevent infections in central venous catheters used in intensive care. 120 ICU patients received either the taurolidine solution, a tigecycline-heparin mix, or plain saline to lock their catheters. The goal was to see which approach best reduced bacterial growth and bloodstream infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- taurolidine-citrate-heparin lock solution
- What this could lead to
- If effective, this could provide a simple way to reduce dangerous catheter infections in ICU patients, potentially saving lives and shortening hospital stays.
- What could go wrong
- This is a small, completed trial with 120 participants, so results may not apply to all ICU settings. The intervention also includes heparin and citrate, which carry bleeding or allergy risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL VENOUS CATHETER INFECTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, El-Gharbia, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict superbug evolution in the ICU?
- A family therapy could curb early psychosis risk in youth
- Yearly TB check may shield vulnerable patients from a hidden threat
- Emergency rooms as prevention hubs: personalized advice may improve health behaviors
- Could a single pill after sex stop STIs in women?
- Can free meal kits from a food pantry boost healthy eating?